Try the Demo today!
| SEC Filing | Insider | Company | Trade Date | Transaction | Shares | Avg. Price | Total | % Holdings | Return |
|---|---|---|---|---|---|---|---|---|---|
| 05-Jan-23 4:01 PM View:  | Mor George Adi Chief Scientific Officer Director | Chemomab Therapeutics Ltd. (CMMB) | 03-Jan-23 | Sale (Planned) | 6,100 | $5.03 | $30,663.50 | (1%) 574.32K to 568.22K | |
| 05-Jan-23 4:01 PM View: | Mor George Adi Chief Scientific Officer Director | Chemomab Therapeutics Ltd. (CMMB) | 03-Jan-23 | Sale (Planned) | 7,700 | $5.03 | $38,706.40 | (1%) 582.02K to 574.32K | |
| 05-Jan-23 4:49 PM View: | Orbimed Israel Gp Ltd. 10% Owner | Chemomab Therapeutics Ltd. (CMMB) | 03-Jan-23 | Sale | 336,900 | $3.58 | $1,207,760.00 | (13%) 2.58M to 2.24M | |
| 17-Nov-22 4:56 PM View: | Mor George Adi Chief Scientific Officer Director | Chemomab Therapeutics Ltd. (CMMB) | 16-Nov-22 | Sale | 257,248 | $2.08 | $536,311.00 | (31%) 839.27K to 582.02K | |
| 17-Nov-22 4:56 PM View: | Mor George Adi Chief Scientific Officer Director | Chemomab Therapeutics Ltd. (CMMB) | 16-Nov-22 | Sale | 324,775 | $2.08 | $677,091.00 | (28%) 1.16M to 839.27K | |
| 18-Nov-22 7:53 AM View: | Cohen Neil Harris Director | Chemomab Therapeutics Ltd. (CMMB) | 16-Nov-22 | Sale | 2,409 | $2.00 | $4,818.00 | (19%) 12.41K to 10.0K | |
| 25-May-22 4:03 PM View: | Maryles Joel Michael Director | Chemomab Therapeutics Ltd. (CMMB) | 24-May-22 | Private Purchase | 433 | $2.88 | $1,247.08 | 43% 1.0K to 1.43K | |
| 19-May-22 4:02 PM View: | Cohen Neil Harris Director | Chemomab Therapeutics Ltd. (CMMB) | 18-May-22 | Private Purchase | 2,000 | $3.19 | $6,380.00 | 19% 10.41K to 12.41K | |
| 21-Mar-22 6:04 AM View: | Maryles Joel Michael Director | Chemomab Therapeutics Ltd. (CMMB) | 18-Mar-22 | Private Purchase | 1,000 | $4.34 | $4,340.00 | 100% 0 to 1.0K | |
| 21-Jun-22 6:01 AM View: | Marvin Donald Executive VP, CFO & COO | Chemomab Therapeutics Ltd. (CMMB) | 16-Mar-22 | Private Purchase | 500 | $3.28 | $1,637.50 | 33% 1.5K to 2.0K | |
| 15-Mar-22 4:10 PM View: | Pfost Dale R Chief Executive Officer Director | Chemomab Therapeutics Ltd. (CMMB) | 14-Mar-22 | Private Purchase | 2,500 | $3.98 | $9,943.00 | 100% 0 to 2.5K | |
| 21-Mar-22 6:02 AM View: | Marvin Donald Executive VP, CFO & COO | Chemomab Therapeutics Ltd. (CMMB) | 14-Mar-22 | Private Purchase | 1,250 | $4.04 | $5,045.00 | 500% 0.25K to 1.5K | |
| 15-Mar-22 4:07 PM View: | Cohen Neil Harris Director | Chemomab Therapeutics Ltd. (CMMB) | 14-Mar-22 | Private Purchase | 6,000 | $4.35 | $26,120.00 | 136% 4.41K to 10.41K | |
| 14-Mar-22 4:20 PM View: | Darvish Nissim Director | Chemomab Therapeutics Ltd. (CMMB) | 11-Mar-22 | Private Purchase | 1,200 | $4.28 | $5,136.00 | 100% 0 to 1.2K | |
| 08-Dec-21 7:29 AM View: | Cohen Neil Harris Director | Chemomab Therapeutics Ltd. (CMMB) | 06-Dec-21 | Market Purchase | 2,000 | $7.43 | $14,860.00 | 83% 2.41K to 4.41K | 6% |
| 18-Mar-21 9:59 PM View: | Orbimed Israel Gp Ltd. 10% Owner | Chemomab Therapeutics Ltd. (CMMB) | 16-Mar-21 | Grant | 288,170 | $17.35 | $4,999,750.00 | 13% 2.29M to 2.58M | |
| 18-Mar-21 9:42 PM View: | Thiel Peter 10% Owner | Chemomab Therapeutics Ltd. (CMMB) | 16-Mar-21 | Purchase | 230,536 | -- | -- | 26% 877.97K to 1.11M | |
| 26-Mar-21 10:27 AM View: | Cohen Neil Harris Director | Chemomab Therapeutics Ltd. (CMMB) | 16-Mar-21 | Purchase | 2,409 | $41.51 | $99,997.60 | 100% 0 to 2.41K |
